A significant association was observed between PD-L1 expression and the clinical stage of the disease (p = 0.048, df = 5, <i>χ2</i> = 11.12), suggesting the potential of PD-L1 as a biomarker for tumor progression. This evidence concerns the gene CD274 and neoplasm.